eFFECTOR Therapeutics, Inc.
EFTR · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 81.5% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -5,149.4% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -5,635.2% | – | – |
| EPS Diluted | -3.31 | -3.42 | -3.36 | -4.37 |
| % Growth | 3.2% | -1.8% | 23.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |